RMD Quote, Financials, Valuation and Earnings

Globus Medical has a net margin of 25.43% compared to ResMed's net margin of 8.28%. ResMed's return on equity of 23.76% beat Globus Medical's return on equity of 2.27%.

ResMed has a consensus price target of $206.05, signalling upside risk potential of 6.68%. On the other hand Globus Medical has an analysts' consensus of $94.23 which suggests that it could grow by 14.04%. Given that Globus Medical has higher upside potential than ResMed, analysts believe Globus Medical is more attractive than ResMed.

ResMed has a beta of 0.684, which suggesting that the stock is 31.593% less volatile than S&P 500. In comparison Globus Medical has a beta of 1.190, suggesting its more volatile than the S&P 500 by 19.035%.

ResMed has a quarterly dividend of $0.53 per share corresponding to a yield of 0.85%. Globus Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ResMed pays 27.65% of its earnings as a dividend. Globus Medical pays out -- of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

ResMed quarterly revenues are $1.2B, which are larger than Globus Medical quarterly revenues of $625.7M. ResMed's net income of $311.4M is higher than Globus Medical's net income of $51.8M. Notably, ResMed's price-to-earnings ratio is 31.43x while Globus Medical's PE ratio is 123.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ResMed is 7.28x versus 4.57x for Globus Medical. Usually stocks with elevated PS ratios are considered overvalued.

Haemonetics has a net margin of 25.43% compared to ResMed's net margin of 9.79%. ResMed's return on equity of 23.76% beat Haemonetics's return on equity of 13.51%.

ResMed has a consensus price target of $206.05, signalling upside risk potential of 6.68%. On the other hand Haemonetics has an analysts' consensus of $110.80 which suggests that it could grow by 46.87%. Given that Haemonetics has higher upside potential than ResMed, analysts believe Haemonetics is more attractive than ResMed.

ResMed has a beta of 0.684, which suggesting that the stock is 31.593% less volatile than S&P 500. In comparison Haemonetics has a beta of 0.383, suggesting its less volatile than the S&P 500 by 61.749%.

ResMed has a quarterly dividend of $0.53 per share corresponding to a yield of 0.85%. Haemonetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ResMed pays 27.65% of its earnings as a dividend. Haemonetics pays out -- of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

ResMed quarterly revenues are $1.2B, which are larger than Haemonetics quarterly revenues of $345.5M. ResMed's net income of $311.4M is higher than Haemonetics's net income of $33.8M. Notably, ResMed's price-to-earnings ratio is 31.43x while Haemonetics's PE ratio is 31.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ResMed is 7.28x versus 2.85x for Haemonetics. Usually stocks with elevated PS ratios are considered overvalued.

Merit Medical Systems has a net margin of 25.43% compared to ResMed's net margin of 8.37%. ResMed's return on equity of 23.76% beat Merit Medical Systems's return on equity of 9.56%.

ResMed has a consensus price target of $206.05, signalling upside risk potential of 6.68%. On the other hand Merit Medical Systems has an analysts' consensus of $113.20 which suggests that it could grow by 15.3%. Given that Merit Medical Systems has higher upside potential than ResMed, analysts believe Merit Medical Systems is more attractive than ResMed.

ResMed has a beta of 0.684, which suggesting that the stock is 31.593% less volatile than S&P 500. In comparison Merit Medical Systems has a beta of 0.844, suggesting its less volatile than the S&P 500 by 15.557%.

ResMed has a quarterly dividend of $0.53 per share corresponding to a yield of 0.85%. Merit Medical Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ResMed pays 27.65% of its earnings as a dividend. Merit Medical Systems pays out -- of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

ResMed quarterly revenues are $1.2B, which are larger than Merit Medical Systems quarterly revenues of $339.8M. ResMed's net income of $311.4M is higher than Merit Medical Systems's net income of $28.4M. Notably, ResMed's price-to-earnings ratio is 31.43x while Merit Medical Systems's PE ratio is 47.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ResMed is 7.28x versus 4.35x for Merit Medical Systems. Usually stocks with elevated PS ratios are considered overvalued.

Zimmer Biomet Holdings has a net margin of 25.43% compared to ResMed's net margin of 13.66%. ResMed's return on equity of 23.76% beat Zimmer Biomet Holdings's return on equity of 8.63%.

ResMed has a consensus price target of $206.05, signalling upside risk potential of 6.68%. On the other hand Zimmer Biomet Holdings has an analysts' consensus of $124.27 which suggests that it could grow by 16.01%. Given that Zimmer Biomet Holdings has higher upside potential than ResMed, analysts believe Zimmer Biomet Holdings is more attractive than ResMed.

ResMed has a beta of 0.684, which suggesting that the stock is 31.593% less volatile than S&P 500. In comparison Zimmer Biomet Holdings has a beta of 1.017, suggesting its more volatile than the S&P 500 by 1.712%.

ResMed has a quarterly dividend of $0.53 per share corresponding to a yield of 0.85%. Zimmer Biomet Holdings offers a yield of 0.9% to investors and pays a quarterly dividend of $0.24 per share. ResMed pays 27.65% of its earnings as a dividend. Zimmer Biomet Holdings pays out 19.62% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

ResMed quarterly revenues are $1.2B, which are smaller than Zimmer Biomet Holdings quarterly revenues of $1.8B. ResMed's net income of $311.4M is higher than Zimmer Biomet Holdings's net income of $249.1M. Notably, ResMed's price-to-earnings ratio is 31.43x while Zimmer Biomet Holdings's PE ratio is 20.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ResMed is 7.28x versus 2.91x for Zimmer Biomet Holdings. Usually stocks with elevated PS ratios are considered overvalued.